CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 81 enrolled
Drug / intervention
docetaxel +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00362882
NCT00362882Phase 2Completed
CompareCT.gov

Randomized Phase II Trial of Sequential Versus Concurrent Docetaxel and PS-341 (NSC 681239) in Previously Treated Non-Small Cell Lung Cancer (NSCLC)

National Cancer Institute (NCI)·interventional·Posted Aug 15, 2006·Updated Dec 5, 2017

In Brief

A Phase 2 clinical trial evaluating docetaxel, bortezomib, and 4 other interventions for Non-small Cell Lung Cancer and 2 related conditions. Completed, enrolled 81 participants across 1 site.

Detailed Summary

This trial is studying two different schedules of docetaxel and bortezomib to compare how well they work in treating patients with progressive or recurrent non-small cell lung cancer. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving docetaxel together with bortezomib may kill more tumor cells

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 15, 2006
Enrollment StartJul 1, 2006
Primary CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 19.9 years ago

Interventions

docetaxeldrug

Given IV

bortezomibdrug

Given IV

laboratory biomarker analysisother

correlative study

immunoenzyme techniqueother

correlative study

immunohistochemistry staining methodother

correlative study

pharmacological studyother

correlative study